Time on Treatment and Survival Outcomes for Patients Treated With First-line Osimertinib vs. Other Tyrosine Kinase Inhibitors, for EGFR Mutation-positive Metastatic Non-small Cell Lung Cancer: Real-world Experience Data
Sarah Sharman Moser, Lior Apter, Josie Solomon, Gabriel Chodick, Miriana Wollner, Nava Siegelmann-Danieli
Research output: Contribution to journal › Article › peer-review
4Scopus
citations
Fingerprint
Dive into the research topics of 'Time on Treatment and Survival Outcomes for Patients Treated With First-line Osimertinib vs. Other Tyrosine Kinase Inhibitors, for EGFR Mutation-positive Metastatic Non-small Cell Lung Cancer: Real-world Experience Data'. Together they form a unique fingerprint.